{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024145","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.887598+00:00","generated_at":"2026-06-21T22:48:31.664495+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aura Biosciences reports Q3 2022 net loss of $15.9M; initiates global Phase 3 trial for bel-sar in choroidal melanoma","bullets":["Net loss $15.9M for Q3 2022 vs $8.8M YoY; cash $111.5M sufficient into 2024.","Research & development expenses $11.3M (+77% YoY); G&A $4.8M (+92% YoY).","Global Phase 3 trial for bel-sar in early-stage choroidal melanoma initiated: 3-arm, masked, ~75 patients, adaptive design.","Positive Phase 2 interim data: tumor growth rate reduction (p=0.0007), 88.9% tumor control rate, favorable safety.","First patient dosed in Phase 1 for NMIBC; initial data expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024145","json":"https://secwatch.observer/filing/0000950170-22-024145.json","markdown":"https://secwatch.observer/filing/0000950170-22-024145.md","text":"https://secwatch.observer/filing/0000950170-22-024145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017022024145/0000950170-22-024145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017022024145/aura-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:48:31.664495+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e34f44053a3a205b84852b494139aa0d6422e2d1","claim":"Aura Biosciences, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Aura Biosciences Inc, (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017022024145/0000950170-22-024145-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}